Phase I: Patients must have histologically confirmed R/R NHL or HL (defined by WHO criteria). Patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are eligible. In addition, patients with NHL other than diffuse large B cell lymphomas (DLBCL) must have received at least 2 prior therapies. Patients with DLBCL and HL will be eligible if there is no available standard therapy. 
Phase II: Patients must have histologically confirmed R/R NHL (as defined by WHO criteria). Patients with NHL other than diffuse large B cell lymphomas (DLBCL) must have received at least 2 prior therapies. Patients with DLBCL will be eligible if there is no available standard therapy. 
Must have received front line chemotherapy. No upper limit for the number of prior therapies 
Evaluable Disease in the Phase I, and measurable disease in the Phase II 
Age > 18 years 
ECOG performance status < 2 
Patients must have adequate organ and marrow function 
Adequate Contraception 
Ability to understand and the willingness to sign a written informed consent document 

NCT02867618_inc_T1
Procedure
histologically
NCT02867618_inc_T2
Value
confirmed
NCT02867618_inc_T3
Condition
NHL
NCT02867618_inc_T4
Condition
HL
NCT02867618_inc_T5
Scope
NHL or HL
NCT02867618_inc_T8
Qualifier
R/R
NCT02867618_inc_T9
Measurement
WHO criteria
NCT02867618_inc_T10
Scope
R/R NHL or HL
NCT02867618_inc_T11
Procedure
chronic lymphocytic leukemia (CLL)
NCT02867618_inc_T12
Procedure
small lymphocytic lymphoma (SLL)
NCT02867618_inc_T14
Condition
NHL
NCT02867618_inc_T15
Condition
diffuse large B cell lymphomas (DLBCL)
NCT02867618_inc_T16
Multiplier
at least 2
NCT02867618_inc_T17
Negation
other than
NCT02867618_inc_T18
Scope
NHL other than diffuse large B cell lymphomas (DLBCL)
NCT02867618_inc_T19
Procedure
therapies
NCT02867618_inc_T20
Temporal
prior
NCT02867618_inc_T22
Condition
DLBCL
NCT02867618_inc_T23
Condition
HL
NCT02867618_inc_T25
Procedure
standard therapy
NCT02867618_inc_T27
Negation
no
NCT02867618_inc_T28
Scope
DLBCL and HL
NCT02867618_inc_T29
Measurement
histologically
NCT02867618_inc_T30
Qualifier
R/R
NCT02867618_inc_T6
Condition
NHL
NCT02867618_inc_T7
Measurement
WHO criteria
NCT02867618_inc_T31
Value
confirmed
NCT02867618_inc_T32
Condition
NHL
NCT02867618_inc_T33
Condition
diffuse large B cell lymphomas (DLBCL)
NCT02867618_inc_T34
Negation
other than
NCT02867618_inc_T35
Multiplier
at least 2
NCT02867618_inc_T36
Temporal
prior
NCT02867618_inc_T37
Procedure
therapies
NCT02867618_inc_T41
Scope
NHL other than diffuse large B cell lymphomas (DLBCL)
NCT02867618_inc_T42
Condition
DLBCL
NCT02867618_inc_T43
Procedure
standard therapy
NCT02867618_inc_T45
Negation
no
NCT02867618_inc_T46
Procedure
chemotherapy
NCT02867618_inc_T47
Qualifier
front line
NCT02867618_inc_T49
Condition
Disease
NCT02867618_inc_T50
Qualifier
Evaluable
NCT02867618_inc_T51
Temporal
in the Phase I
NCT02867618_inc_T52
Temporal
in the Phase II
NCT02867618_inc_T53
Qualifier
measurable
NCT02867618_inc_T54
Person
Age
NCT02867618_inc_T55
Value
> 18 years
NCT02867618_inc_T56
Measurement
ECOG performance status
NCT02867618_inc_T57
Value
< 2
NCT02867618_inc_T58
Measurement
organ function
NCT02867618_inc_T59
Measurement
marrow function
NCT02867618_inc_T60
Value
adequate
NCT02867618_inc_T63
Procedure
Contraception
NCT02867618_inc_T64
Qualifier
Adequate